Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference
August 08 2017 - 8:00AM
Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that
its President, Chief Operating Officer and Chief Medical Officer,
Evan Loh, MD, will present at the Wedbush PacGrow Healthcare
Conference on Tuesday, August 15 from 10:20 a.m. to 10:50 a.m. The
conference is being held at Le Parker Meridien Hotel in New York,
New York. Paratek is a biopharmaceutical company focused on the
development and commercialization of innovative therapies based
upon tetracycline chemistry.
To access the live webcast of Paratek's session, please visit
http://wsw.com/webcast/wedbush33/prtk. Please connect to the
web site at least 15 minutes prior to the live presentation to
ensure adequate time for any software downloads that may be
necessary to listen to the webcast. A replay of the webcast can be
accessed in the investor section of http://www.paratekpharma.com
for 90 days following the live presentation. About
ParatekParatek Pharmaceuticals, Inc. is a
biopharmaceutical company focused on the development and
commercialization of innovative therapies based upon its expertise
in novel tetracycline chemistry. The Company’s lead product
candidate, omadacycline, is a new, once-daily oral and intravenous
broad-spectrum antibiotic being developed for the treatment of
serious community-acquired bacterial infections, including
community-acquired bacterial pneumonia (CABP), acute bacterial skin
and skin structure infections (ABSSSI), and urinary
tract infections. Omadacycline has been granted Qualified
Infectious Disease Product designation and Fast Track status by
the U.S. Food and Drug Administration for the target
indications. Paratek has completed Phase 3 development activities
for omadacycline in CABP and ABSSSI and is preparing to submit
marketing applications in the United States and European Union.
Paratek has licensed rights for omadacycline to Zai Lab for the
greater China region, and retains all remaining global rights.
Under a research agreement with the U.S. Department of Defense,
omadacycline also is being studied against pathogenic agents
causing infectious diseases of public health and biodefense
importance, including plague and anthrax. Paratek's second
Phase 3 product candidate, sarecycline, is being developed by
Allergan in the U.S. as a new once-daily oral therapy for the
treatment of acne. Allergan has completed Phase 3 development
activities for sarecycline and is preparing a new drug application
for submission to the U.S. Food and Drug Administration. Paratek
retains all ex-U.S. rights to sarecycline. Recognizing the
serious threat of bacterial infections, Paratek is dedicated to
providing solutions that enable positive outcomes and lead to
better patient stories. For more information,
visit www.paratekpharma.com or follow @ParatekPharma on
Twitter.
CONTACTS:
Media Relations: |
|
Investor
Relations: |
Michael Lampe |
|
Hans Vitzthum |
(484) 575-5040 |
|
LifeSci Advisors,
LLC. |
michael@scientpr.com |
|
212-915-2568 |
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2024 to May 2024
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From May 2023 to May 2024